Expression profile of messenger and micro RNAs related to the histaminergic system in patients with five subtypes of breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study explored messenger ribonucleic acid (mRNA) and micro RNA (miRNA) in Polish women with breast cancer subtypes. Key histaminergic system genes and their miRNA regulators were identified as potential diagnostic markers and therapeutic targets.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Breast cancer is classified into subtypes based on receptor status (ER, PR, HER2) and proliferation (Ki67).
- The histaminergic system shows therapeutic potential in preclinical breast cancer models.
- Understanding gene expression in diverse breast cancer subtypes is crucial for targeted therapies.
Purpose Of The Study
- To analyze messenger ribonucleic acid (mRNA) and micro RNA (miRNA) expression profiles related to the histaminergic system in five breast cancer subtypes.
- To identify potential molecular markers and therapeutic targets within the histaminergic system for breast cancer.
- To investigate the regulatory roles of specific miRNAs on key histaminergic genes in breast cancer.
Main Methods
- Microarray analysis of mRNA and miRNA associated with the histaminergic system in tumor tissues from 5 breast cancer subtypes (Luminal A, Luminal B, HER2+, TNBC) and control samples.
- Real-time polymerase chain reaction (RT-PCR) for selected gene expression.
- Enzyme-linked immunosorbent assay (ELISA) for histamine receptor (HRH1, HRH2, HRH4) quantification.
Main Results
- Nine mRNAs (HRH1, HRH2, HRH4, HNMT, HTR6, EDN1, EDNRA, ADA, SLC3A2) were significantly differentiated in breast cancer compared to controls.
- Specific miRNAs were predicted to regulate key genes: hsa-miR-34a for HRH1, hsa-miR-3140-5p/hsa-miR-4251 for HRH2, hsa-miR-1-3p for HRH4/EDN1, hsa-miR-382 for HNMT, hsa-miR-34a/hsa-miR-16 for EDNRA, hsa-miR-650 for HTR6, and hsa-miR-1275 for ADA/SLC23A2/HRH1.
- The identified mRNA and miRNA transcripts show potential as molecular markers and therapeutic targets in breast cancer.
Conclusions
- Specific histaminergic system-related mRNA and miRNA expression profiles are altered in different breast cancer subtypes.
- Identified miRNA-mRNA interactions suggest novel regulatory pathways within the histaminergic system in breast cancer.
- These molecular signatures represent promising candidates for future diagnostic and therapeutic strategies in breast cancer treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...